nodes	percent_of_prediction	percent_of_DWPC	metapath
Rifaximin—NR1I2—Ethinyl Estradiol—osteoporosis	0.388	0.505	CbGbCtD
Rifaximin—NR1I2—Estradiol—osteoporosis	0.25	0.326	CbGbCtD
Rifaximin—CYP3A4—Estropipate—osteoporosis	0.0236	0.0307	CbGbCtD
Rifaximin—CYP3A4—Calcitriol—osteoporosis	0.0236	0.0307	CbGbCtD
Rifaximin—CYP3A4—Ergocalciferol—osteoporosis	0.0189	0.0246	CbGbCtD
Rifaximin—CYP3A4—Raloxifene—osteoporosis	0.0158	0.0205	CbGbCtD
Rifaximin—NR1I2—Drug Induction of Bile Acid Pathway—SLC51A—osteoporosis	0.0152	0.477	CbGpPWpGaD
Rifaximin—CYP3A4—Ethinyl Estradiol—osteoporosis	0.0152	0.0198	CbGbCtD
Rifaximin—CYP3A4—Cholecalciferol—osteoporosis	0.0122	0.0158	CbGbCtD
Rifaximin—CYP3A4—Conjugated Estrogens—osteoporosis	0.0112	0.0145	CbGbCtD
Rifaximin—CYP3A4—Estradiol—osteoporosis	0.00981	0.0128	CbGbCtD
Rifaximin—NR1I2—Drug Induction of Bile Acid Pathway—VDR—osteoporosis	0.00244	0.0762	CbGpPWpGaD
Rifaximin—CYP3A4—Drug Induction of Bile Acid Pathway—SLC51A—osteoporosis	0.00176	0.0551	CbGpPWpGaD
Rifaximin—NR1I2—Nuclear Receptors—ESR2—osteoporosis	0.00161	0.0504	CbGpPWpGaD
Rifaximin—NR1I2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—osteoporosis	0.0014	0.0437	CbGpPWpGaD
Rifaximin—NR1I2—Nuclear Receptors—VDR—osteoporosis	0.00128	0.04	CbGpPWpGaD
Rifaximin—NR1I2—Nuclear Receptor transcription pathway—ESR2—osteoporosis	0.00127	0.0398	CbGpPWpGaD
Rifaximin—NR1I2—Nuclear Receptor transcription pathway—VDR—osteoporosis	0.00101	0.0316	CbGpPWpGaD
Rifaximin—NR1I2—Nuclear Receptors—ESR1—osteoporosis	0.000978	0.0306	CbGpPWpGaD
Rifaximin—NR1I2—Nuclear Receptor transcription pathway—ESR1—osteoporosis	0.000773	0.0242	CbGpPWpGaD
Rifaximin—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—osteoporosis	0.000282	0.00881	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—U2AF1—osteoporosis	0.000276	0.00865	CbGpPWpGaD
Rifaximin—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP27A1—osteoporosis	0.000224	0.007	CbGpPWpGaD
Rifaximin—CYP3A4—Oxidation by Cytochrome P450—CYP27A1—osteoporosis	0.000221	0.0069	CbGpPWpGaD
Rifaximin—NR1I2—Generic Transcription Pathway—ESR2—osteoporosis	0.00022	0.00688	CbGpPWpGaD
Rifaximin—CYP3A4—Farnesoid X Receptor  Pathway—IRS2—osteoporosis	0.000211	0.00659	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—RPL24—osteoporosis	0.000205	0.00643	CbGpPWpGaD
Rifaximin—Pharyngitis—Estradiol—osteoporosis	0.000197	0.000989	CcSEcCtD
Rifaximin—Hypersensitivity—Estropipate—osteoporosis	0.000196	0.000986	CcSEcCtD
Rifaximin—Nervous system disorder—Pamidronate—osteoporosis	0.000196	0.000986	CcSEcCtD
Rifaximin—Urinary tract disorder—Estradiol—osteoporosis	0.000196	0.000984	CcSEcCtD
Rifaximin—Vomiting—Etidronic acid—osteoporosis	0.000196	0.000983	CcSEcCtD
Rifaximin—Cough—Zoledronate—osteoporosis	0.000195	0.000982	CcSEcCtD
Rifaximin—Oedema peripheral—Estradiol—osteoporosis	0.000195	0.000981	CcSEcCtD
Rifaximin—Urethral disorder—Estradiol—osteoporosis	0.000194	0.000976	CcSEcCtD
Rifaximin—Rash—Etidronic acid—osteoporosis	0.000194	0.000975	CcSEcCtD
Rifaximin—Dermatitis—Etidronic acid—osteoporosis	0.000194	0.000974	CcSEcCtD
Rifaximin—Vertigo—Conjugated Estrogens—osteoporosis	0.000194	0.000973	CcSEcCtD
Rifaximin—Hyperhidrosis—Pamidronate—osteoporosis	0.000193	0.000972	CcSEcCtD
Rifaximin—Syncope—Conjugated Estrogens—osteoporosis	0.000193	0.000972	CcSEcCtD
Rifaximin—Hypersensitivity—Alendronate—osteoporosis	0.000193	0.000971	CcSEcCtD
Rifaximin—Headache—Etidronic acid—osteoporosis	0.000193	0.000969	CcSEcCtD
Rifaximin—Musculoskeletal discomfort—Risedronate—osteoporosis	0.000192	0.000963	CcSEcCtD
Rifaximin—Asthenia—Estropipate—osteoporosis	0.000191	0.00096	CcSEcCtD
Rifaximin—Anorexia—Pamidronate—osteoporosis	0.000191	0.000958	CcSEcCtD
Rifaximin—Arthralgia—Zoledronate—osteoporosis	0.000191	0.000958	CcSEcCtD
Rifaximin—Myalgia—Zoledronate—osteoporosis	0.000191	0.000958	CcSEcCtD
Rifaximin—Chest pain—Zoledronate—osteoporosis	0.000191	0.000958	CcSEcCtD
Rifaximin—Insomnia—Risedronate—osteoporosis	0.00019	0.000956	CcSEcCtD
Rifaximin—Loss of consciousness—Conjugated Estrogens—osteoporosis	0.00019	0.000952	CcSEcCtD
Rifaximin—Unspecified disorder of skin and subcutaneous tissue—Zoledronate—osteoporosis	0.000189	0.000951	CcSEcCtD
Rifaximin—Pruritus—Estropipate—osteoporosis	0.000188	0.000947	CcSEcCtD
Rifaximin—Discomfort—Zoledronate—osteoporosis	0.000188	0.000946	CcSEcCtD
Rifaximin—Asthenia—Alendronate—osteoporosis	0.000188	0.000946	CcSEcCtD
Rifaximin—Hypersensitivity—Ibandronate—osteoporosis	0.000188	0.000945	CcSEcCtD
Rifaximin—Cough—Conjugated Estrogens—osteoporosis	0.000188	0.000945	CcSEcCtD
Rifaximin—Dyspnoea—Risedronate—osteoporosis	0.000188	0.000943	CcSEcCtD
Rifaximin—Hypotension—Pamidronate—osteoporosis	0.000187	0.000939	CcSEcCtD
Rifaximin—Dry mouth—Zoledronate—osteoporosis	0.000187	0.000937	CcSEcCtD
Rifaximin—Gastrointestinal disorder—Ethinyl Estradiol—osteoporosis	0.000186	0.000936	CcSEcCtD
Rifaximin—Fatigue—Ethinyl Estradiol—osteoporosis	0.000186	0.000935	CcSEcCtD
Rifaximin—Pruritus—Alendronate—osteoporosis	0.000186	0.000932	CcSEcCtD
Rifaximin—Tinnitus—Estradiol—osteoporosis	0.000185	0.000929	CcSEcCtD
Rifaximin—Constipation—Ethinyl Estradiol—osteoporosis	0.000185	0.000928	CcSEcCtD
Rifaximin—Confusional state—Zoledronate—osteoporosis	0.000184	0.000926	CcSEcCtD
Rifaximin—Hypersensitivity—Calcitriol—osteoporosis	0.000184	0.000925	CcSEcCtD
Rifaximin—Flushing—Estradiol—osteoporosis	0.000184	0.000924	CcSEcCtD
Rifaximin—Myalgia—Conjugated Estrogens—osteoporosis	0.000184	0.000922	CcSEcCtD
Rifaximin—Chest pain—Conjugated Estrogens—osteoporosis	0.000184	0.000922	CcSEcCtD
Rifaximin—Arthralgia—Conjugated Estrogens—osteoporosis	0.000184	0.000922	CcSEcCtD
Rifaximin—Asthenia—Ibandronate—osteoporosis	0.000183	0.000921	CcSEcCtD
Rifaximin—Nausea—Etidronic acid—osteoporosis	0.000183	0.000919	CcSEcCtD
Rifaximin—Anaphylactic shock—Zoledronate—osteoporosis	0.000183	0.000918	CcSEcCtD
Rifaximin—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—osteoporosis	0.000182	0.000916	CcSEcCtD
Rifaximin—Musculoskeletal discomfort—Pamidronate—osteoporosis	0.000182	0.000916	CcSEcCtD
Rifaximin—Diarrhoea—Estropipate—osteoporosis	0.000182	0.000916	CcSEcCtD
Rifaximin—Gastrointestinal disorder—Risedronate—osteoporosis	0.000182	0.000913	CcSEcCtD
Rifaximin—Infection—Zoledronate—osteoporosis	0.000182	0.000912	CcSEcCtD
Rifaximin—Fatigue—Risedronate—osteoporosis	0.000182	0.000912	CcSEcCtD
Rifaximin—CYP3A4—Phase 1 - Functionalization of compounds—CYP27A1—osteoporosis	0.000181	0.00567	CbGpPWpGaD
Rifaximin—Insomnia—Pamidronate—osteoporosis	0.000181	0.000909	CcSEcCtD
Rifaximin—Pruritus—Ibandronate—osteoporosis	0.000181	0.000908	CcSEcCtD
Rifaximin—Pain—Risedronate—osteoporosis	0.00018	0.000904	CcSEcCtD
Rifaximin—Constipation—Risedronate—osteoporosis	0.00018	0.000904	CcSEcCtD
Rifaximin—Angiopathy—Estradiol—osteoporosis	0.00018	0.000904	CcSEcCtD
Rifaximin—Shock—Zoledronate—osteoporosis	0.00018	0.000903	CcSEcCtD
Rifaximin—Diarrhoea—Alendronate—osteoporosis	0.00018	0.000902	CcSEcCtD
Rifaximin—Asthenia—Calcitriol—osteoporosis	0.000179	0.000901	CcSEcCtD
Rifaximin—Nervous system disorder—Zoledronate—osteoporosis	0.000179	0.000901	CcSEcCtD
Rifaximin—Mediastinal disorder—Estradiol—osteoporosis	0.000179	0.000898	CcSEcCtD
Rifaximin—Dyspnoea—Pamidronate—osteoporosis	0.000178	0.000896	CcSEcCtD
Rifaximin—Feeling abnormal—Ethinyl Estradiol—osteoporosis	0.000178	0.000894	CcSEcCtD
Rifaximin—Skin disorder—Zoledronate—osteoporosis	0.000178	0.000892	CcSEcCtD
Rifaximin—Pruritus—Calcitriol—osteoporosis	0.000177	0.000889	CcSEcCtD
Rifaximin—Hyperhidrosis—Zoledronate—osteoporosis	0.000177	0.000888	CcSEcCtD
Rifaximin—Gastrointestinal pain—Ethinyl Estradiol—osteoporosis	0.000177	0.000887	CcSEcCtD
Rifaximin—Diarrhoea—Raloxifene—osteoporosis	0.000177	0.000887	CcSEcCtD
Rifaximin—Dizziness—Estropipate—osteoporosis	0.000176	0.000885	CcSEcCtD
Rifaximin—Anaphylactic shock—Conjugated Estrogens—osteoporosis	0.000176	0.000884	CcSEcCtD
Rifaximin—Infection—Conjugated Estrogens—osteoporosis	0.000175	0.000878	CcSEcCtD
Rifaximin—Diarrhoea—Ibandronate—osteoporosis	0.000175	0.000878	CcSEcCtD
Rifaximin—NR1I2—Generic Transcription Pathway—VDR—osteoporosis	0.000175	0.00546	CbGpPWpGaD
Rifaximin—Anorexia—Zoledronate—osteoporosis	0.000174	0.000875	CcSEcCtD
Rifaximin—Decreased appetite—Pamidronate—osteoporosis	0.000174	0.000874	CcSEcCtD
Rifaximin—Mental disorder—Estradiol—osteoporosis	0.000174	0.000873	CcSEcCtD
Rifaximin—Dizziness—Alendronate—osteoporosis	0.000174	0.000872	CcSEcCtD
Rifaximin—Shock—Conjugated Estrogens—osteoporosis	0.000173	0.00087	CcSEcCtD
Rifaximin—Gastrointestinal disorder—Pamidronate—osteoporosis	0.000173	0.000868	CcSEcCtD
Rifaximin—Nervous system disorder—Conjugated Estrogens—osteoporosis	0.000173	0.000867	CcSEcCtD
Rifaximin—Malnutrition—Estradiol—osteoporosis	0.000173	0.000867	CcSEcCtD
Rifaximin—Fatigue—Pamidronate—osteoporosis	0.000173	0.000867	CcSEcCtD
Rifaximin—Gastrointestinal pain—Risedronate—osteoporosis	0.000172	0.000865	CcSEcCtD
Rifaximin—Urticaria—Ethinyl Estradiol—osteoporosis	0.000172	0.000862	CcSEcCtD
Rifaximin—Pain—Pamidronate—osteoporosis	0.000171	0.00086	CcSEcCtD
Rifaximin—Constipation—Pamidronate—osteoporosis	0.000171	0.00086	CcSEcCtD
Rifaximin—Diarrhoea—Calcitriol—osteoporosis	0.000171	0.000859	CcSEcCtD
Rifaximin—Skin disorder—Conjugated Estrogens—osteoporosis	0.000171	0.000859	CcSEcCtD
Rifaximin—Hypotension—Zoledronate—osteoporosis	0.000171	0.000858	CcSEcCtD
Rifaximin—Body temperature increased—Ethinyl Estradiol—osteoporosis	0.000171	0.000857	CcSEcCtD
Rifaximin—Abdominal pain—Ethinyl Estradiol—osteoporosis	0.000171	0.000857	CcSEcCtD
Rifaximin—Dizziness—Raloxifene—osteoporosis	0.000171	0.000857	CcSEcCtD
Rifaximin—Hyperhidrosis—Conjugated Estrogens—osteoporosis	0.00017	0.000855	CcSEcCtD
Rifaximin—Flatulence—Estradiol—osteoporosis	0.00017	0.000854	CcSEcCtD
Rifaximin—Vomiting—Estropipate—osteoporosis	0.000169	0.000851	CcSEcCtD
Rifaximin—Dizziness—Ibandronate—osteoporosis	0.000169	0.000849	CcSEcCtD
Rifaximin—Rash—Estropipate—osteoporosis	0.000168	0.000844	CcSEcCtD
Rifaximin—Dermatitis—Estropipate—osteoporosis	0.000168	0.000843	CcSEcCtD
Rifaximin—Anorexia—Conjugated Estrogens—osteoporosis	0.000168	0.000843	CcSEcCtD
Rifaximin—Urticaria—Risedronate—osteoporosis	0.000167	0.00084	CcSEcCtD
Rifaximin—Back pain—Estradiol—osteoporosis	0.000167	0.000839	CcSEcCtD
Rifaximin—Headache—Estropipate—osteoporosis	0.000167	0.000838	CcSEcCtD
Rifaximin—Vomiting—Alendronate—osteoporosis	0.000167	0.000838	CcSEcCtD
Rifaximin—Musculoskeletal discomfort—Zoledronate—osteoporosis	0.000167	0.000837	CcSEcCtD
Rifaximin—Abdominal pain—Risedronate—osteoporosis	0.000166	0.000836	CcSEcCtD
Rifaximin—Body temperature increased—Risedronate—osteoporosis	0.000166	0.000836	CcSEcCtD
Rifaximin—Muscle spasms—Estradiol—osteoporosis	0.000166	0.000834	CcSEcCtD
Rifaximin—Rash—Alendronate—osteoporosis	0.000165	0.000831	CcSEcCtD
Rifaximin—Insomnia—Zoledronate—osteoporosis	0.000165	0.000831	CcSEcCtD
Rifaximin—Dermatitis—Alendronate—osteoporosis	0.000165	0.00083	CcSEcCtD
Rifaximin—Feeling abnormal—Pamidronate—osteoporosis	0.000165	0.000828	CcSEcCtD
Rifaximin—Hypotension—Conjugated Estrogens—osteoporosis	0.000165	0.000826	CcSEcCtD
Rifaximin—Headache—Alendronate—osteoporosis	0.000164	0.000826	CcSEcCtD
Rifaximin—Vomiting—Raloxifene—osteoporosis	0.000164	0.000824	CcSEcCtD
Rifaximin—Gastrointestinal pain—Pamidronate—osteoporosis	0.000164	0.000822	CcSEcCtD
Rifaximin—Dyspnoea—Zoledronate—osteoporosis	0.000163	0.000819	CcSEcCtD
Rifaximin—Rash—Raloxifene—osteoporosis	0.000163	0.000817	CcSEcCtD
Rifaximin—Dermatitis—Raloxifene—osteoporosis	0.000163	0.000817	CcSEcCtD
Rifaximin—Vomiting—Ibandronate—osteoporosis	0.000162	0.000816	CcSEcCtD
Rifaximin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—osteoporosis	0.000162	0.00506	CbGpPWpGaD
Rifaximin—Tremor—Estradiol—osteoporosis	0.000162	0.000812	CcSEcCtD
Rifaximin—Headache—Raloxifene—osteoporosis	0.000162	0.000812	CcSEcCtD
Rifaximin—Rash—Ibandronate—osteoporosis	0.000161	0.000809	CcSEcCtD
Rifaximin—Dermatitis—Ibandronate—osteoporosis	0.000161	0.000808	CcSEcCtD
Rifaximin—Musculoskeletal discomfort—Conjugated Estrogens—osteoporosis	0.00016	0.000806	CcSEcCtD
Rifaximin—Ill-defined disorder—Estradiol—osteoporosis	0.00016	0.000804	CcSEcCtD
Rifaximin—Headache—Ibandronate—osteoporosis	0.00016	0.000804	CcSEcCtD
Rifaximin—Insomnia—Conjugated Estrogens—osteoporosis	0.000159	0.0008	CcSEcCtD
Rifaximin—Hypersensitivity—Ethinyl Estradiol—osteoporosis	0.000159	0.000799	CcSEcCtD
Rifaximin—Vomiting—Calcitriol—osteoporosis	0.000159	0.000799	CcSEcCtD
Rifaximin—Decreased appetite—Zoledronate—osteoporosis	0.000159	0.000798	CcSEcCtD
Rifaximin—Nausea—Estropipate—osteoporosis	0.000158	0.000795	CcSEcCtD
Rifaximin—Abdominal pain—Pamidronate—osteoporosis	0.000158	0.000795	CcSEcCtD
Rifaximin—Body temperature increased—Pamidronate—osteoporosis	0.000158	0.000795	CcSEcCtD
Rifaximin—Gastrointestinal disorder—Zoledronate—osteoporosis	0.000158	0.000793	CcSEcCtD
Rifaximin—Angioedema—Estradiol—osteoporosis	0.000158	0.000792	CcSEcCtD
Rifaximin—Rash—Calcitriol—osteoporosis	0.000158	0.000792	CcSEcCtD
Rifaximin—Fatigue—Zoledronate—osteoporosis	0.000158	0.000792	CcSEcCtD
Rifaximin—Dermatitis—Calcitriol—osteoporosis	0.000158	0.000791	CcSEcCtD
Rifaximin—Dyspnoea—Conjugated Estrogens—osteoporosis	0.000157	0.000788	CcSEcCtD
Rifaximin—Headache—Calcitriol—osteoporosis	0.000157	0.000787	CcSEcCtD
Rifaximin—Constipation—Zoledronate—osteoporosis	0.000156	0.000785	CcSEcCtD
Rifaximin—Pain—Zoledronate—osteoporosis	0.000156	0.000785	CcSEcCtD
Rifaximin—Nausea—Alendronate—osteoporosis	0.000156	0.000783	CcSEcCtD
Rifaximin—Malaise—Estradiol—osteoporosis	0.000156	0.000782	CcSEcCtD
Rifaximin—Hypersensitivity—Risedronate—osteoporosis	0.000155	0.000779	CcSEcCtD
Rifaximin—Vertigo—Estradiol—osteoporosis	0.000155	0.000779	CcSEcCtD
Rifaximin—Asthenia—Ethinyl Estradiol—osteoporosis	0.000155	0.000778	CcSEcCtD
Rifaximin—Syncope—Estradiol—osteoporosis	0.000155	0.000778	CcSEcCtD
Rifaximin—Nausea—Raloxifene—osteoporosis	0.000153	0.00077	CcSEcCtD
Rifaximin—Decreased appetite—Conjugated Estrogens—osteoporosis	0.000153	0.000769	CcSEcCtD
Rifaximin—Pruritus—Ethinyl Estradiol—osteoporosis	0.000153	0.000767	CcSEcCtD
Rifaximin—Gastrointestinal disorder—Conjugated Estrogens—osteoporosis	0.000152	0.000763	CcSEcCtD
Rifaximin—Fatigue—Conjugated Estrogens—osteoporosis	0.000152	0.000762	CcSEcCtD
Rifaximin—Nausea—Ibandronate—osteoporosis	0.000152	0.000762	CcSEcCtD
Rifaximin—Loss of consciousness—Estradiol—osteoporosis	0.000152	0.000762	CcSEcCtD
Rifaximin—Asthenia—Risedronate—osteoporosis	0.000151	0.000759	CcSEcCtD
Rifaximin—Feeling abnormal—Zoledronate—osteoporosis	0.000151	0.000757	CcSEcCtD
Rifaximin—Cough—Estradiol—osteoporosis	0.000151	0.000757	CcSEcCtD
Rifaximin—Pain—Conjugated Estrogens—osteoporosis	0.000151	0.000756	CcSEcCtD
Rifaximin—Constipation—Conjugated Estrogens—osteoporosis	0.000151	0.000756	CcSEcCtD
Rifaximin—Gastrointestinal pain—Zoledronate—osteoporosis	0.00015	0.000751	CcSEcCtD
Rifaximin—Pruritus—Risedronate—osteoporosis	0.000149	0.000748	CcSEcCtD
Rifaximin—Nausea—Calcitriol—osteoporosis	0.000149	0.000746	CcSEcCtD
Rifaximin—Diarrhoea—Ethinyl Estradiol—osteoporosis	0.000148	0.000742	CcSEcCtD
Rifaximin—Hypersensitivity—Pamidronate—osteoporosis	0.000147	0.000741	CcSEcCtD
Rifaximin—Myalgia—Estradiol—osteoporosis	0.000147	0.000738	CcSEcCtD
Rifaximin—Chest pain—Estradiol—osteoporosis	0.000147	0.000738	CcSEcCtD
Rifaximin—Arthralgia—Estradiol—osteoporosis	0.000147	0.000738	CcSEcCtD
Rifaximin—Unspecified disorder of skin and subcutaneous tissue—Estradiol—osteoporosis	0.000146	0.000733	CcSEcCtD
Rifaximin—CYP3A4—Tryptophan metabolism—CYP19A1—osteoporosis	0.000145	0.00455	CbGpPWpGaD
Rifaximin—Urticaria—Zoledronate—osteoporosis	0.000145	0.000729	CcSEcCtD
Rifaximin—Discomfort—Estradiol—osteoporosis	0.000145	0.000729	CcSEcCtD
Rifaximin—Abdominal pain—Zoledronate—osteoporosis	0.000145	0.000726	CcSEcCtD
Rifaximin—Body temperature increased—Zoledronate—osteoporosis	0.000145	0.000726	CcSEcCtD
Rifaximin—Diarrhoea—Risedronate—osteoporosis	0.000144	0.000724	CcSEcCtD
Rifaximin—Gastrointestinal pain—Conjugated Estrogens—osteoporosis	0.000144	0.000723	CcSEcCtD
Rifaximin—Dry mouth—Estradiol—osteoporosis	0.000144	0.000722	CcSEcCtD
Rifaximin—Asthenia—Pamidronate—osteoporosis	0.000144	0.000721	CcSEcCtD
Rifaximin—Dizziness—Ethinyl Estradiol—osteoporosis	0.000143	0.000717	CcSEcCtD
Rifaximin—Confusional state—Estradiol—osteoporosis	0.000142	0.000714	CcSEcCtD
Rifaximin—Pruritus—Pamidronate—osteoporosis	0.000142	0.000711	CcSEcCtD
Rifaximin—Anaphylactic shock—Estradiol—osteoporosis	0.000141	0.000708	CcSEcCtD
Rifaximin—Infection—Estradiol—osteoporosis	0.00014	0.000703	CcSEcCtD
Rifaximin—Urticaria—Conjugated Estrogens—osteoporosis	0.00014	0.000702	CcSEcCtD
Rifaximin—Dizziness—Risedronate—osteoporosis	0.000139	0.000699	CcSEcCtD
Rifaximin—Abdominal pain—Conjugated Estrogens—osteoporosis	0.000139	0.000699	CcSEcCtD
Rifaximin—Body temperature increased—Conjugated Estrogens—osteoporosis	0.000139	0.000699	CcSEcCtD
Rifaximin—Shock—Estradiol—osteoporosis	0.000139	0.000696	CcSEcCtD
Rifaximin—Nervous system disorder—Estradiol—osteoporosis	0.000138	0.000694	CcSEcCtD
Rifaximin—Vomiting—Ethinyl Estradiol—osteoporosis	0.000137	0.00069	CcSEcCtD
Rifaximin—Diarrhoea—Pamidronate—osteoporosis	0.000137	0.000688	CcSEcCtD
Rifaximin—Skin disorder—Estradiol—osteoporosis	0.000137	0.000687	CcSEcCtD
Rifaximin—Hyperhidrosis—Estradiol—osteoporosis	0.000136	0.000684	CcSEcCtD
Rifaximin—Rash—Ethinyl Estradiol—osteoporosis	0.000136	0.000684	CcSEcCtD
Rifaximin—Dermatitis—Ethinyl Estradiol—osteoporosis	0.000136	0.000683	CcSEcCtD
Rifaximin—Headache—Ethinyl Estradiol—osteoporosis	0.000135	0.000679	CcSEcCtD
Rifaximin—Hypersensitivity—Zoledronate—osteoporosis	0.000135	0.000677	CcSEcCtD
Rifaximin—Vomiting—Risedronate—osteoporosis	0.000134	0.000672	CcSEcCtD
Rifaximin—NR1I2—Generic Transcription Pathway—ESR1—osteoporosis	0.000133	0.00417	CbGpPWpGaD
Rifaximin—Rash—Risedronate—osteoporosis	0.000133	0.000667	CcSEcCtD
Rifaximin—Dermatitis—Risedronate—osteoporosis	0.000133	0.000666	CcSEcCtD
Rifaximin—Dizziness—Pamidronate—osteoporosis	0.000132	0.000665	CcSEcCtD
Rifaximin—Headache—Risedronate—osteoporosis	0.000132	0.000662	CcSEcCtD
Rifaximin—Asthenia—Zoledronate—osteoporosis	0.000131	0.000659	CcSEcCtD
Rifaximin—Hypersensitivity—Conjugated Estrogens—osteoporosis	0.00013	0.000651	CcSEcCtD
Rifaximin—Pruritus—Zoledronate—osteoporosis	0.000129	0.00065	CcSEcCtD
Rifaximin—Musculoskeletal discomfort—Estradiol—osteoporosis	0.000128	0.000645	CcSEcCtD
Rifaximin—Nausea—Ethinyl Estradiol—osteoporosis	0.000128	0.000644	CcSEcCtD
Rifaximin—Insomnia—Estradiol—osteoporosis	0.000127	0.00064	CcSEcCtD
Rifaximin—Vomiting—Pamidronate—osteoporosis	0.000127	0.000639	CcSEcCtD
Rifaximin—Asthenia—Conjugated Estrogens—osteoporosis	0.000126	0.000634	CcSEcCtD
Rifaximin—Rash—Pamidronate—osteoporosis	0.000126	0.000634	CcSEcCtD
Rifaximin—Dermatitis—Pamidronate—osteoporosis	0.000126	0.000633	CcSEcCtD
Rifaximin—Dyspnoea—Estradiol—osteoporosis	0.000126	0.000631	CcSEcCtD
Rifaximin—Headache—Pamidronate—osteoporosis	0.000125	0.00063	CcSEcCtD
Rifaximin—Diarrhoea—Zoledronate—osteoporosis	0.000125	0.000628	CcSEcCtD
Rifaximin—Nausea—Risedronate—osteoporosis	0.000125	0.000628	CcSEcCtD
Rifaximin—Pruritus—Conjugated Estrogens—osteoporosis	0.000125	0.000626	CcSEcCtD
Rifaximin—Decreased appetite—Estradiol—osteoporosis	0.000122	0.000615	CcSEcCtD
Rifaximin—Gastrointestinal disorder—Estradiol—osteoporosis	0.000122	0.000611	CcSEcCtD
Rifaximin—Fatigue—Estradiol—osteoporosis	0.000121	0.00061	CcSEcCtD
Rifaximin—Dizziness—Zoledronate—osteoporosis	0.000121	0.000607	CcSEcCtD
Rifaximin—Pain—Estradiol—osteoporosis	0.00012	0.000605	CcSEcCtD
Rifaximin—Constipation—Estradiol—osteoporosis	0.00012	0.000605	CcSEcCtD
Rifaximin—Diarrhoea—Conjugated Estrogens—osteoporosis	0.00012	0.000605	CcSEcCtD
Rifaximin—Nausea—Pamidronate—osteoporosis	0.000119	0.000597	CcSEcCtD
Rifaximin—NR1I2—Gene Expression—PSMA5—osteoporosis	0.000119	0.00371	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—PSMA2—osteoporosis	0.000119	0.00371	CbGpPWpGaD
Rifaximin—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—osteoporosis	0.000118	0.00367	CbGpPWpGaD
Rifaximin—Dizziness—Conjugated Estrogens—osteoporosis	0.000116	0.000585	CcSEcCtD
Rifaximin—Vomiting—Zoledronate—osteoporosis	0.000116	0.000584	CcSEcCtD
Rifaximin—Feeling abnormal—Estradiol—osteoporosis	0.000116	0.000583	CcSEcCtD
Rifaximin—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—osteoporosis	0.000116	0.00363	CbGpPWpGaD
Rifaximin—Rash—Zoledronate—osteoporosis	0.000115	0.000579	CcSEcCtD
Rifaximin—Gastrointestinal pain—Estradiol—osteoporosis	0.000115	0.000579	CcSEcCtD
Rifaximin—Dermatitis—Zoledronate—osteoporosis	0.000115	0.000578	CcSEcCtD
Rifaximin—Headache—Zoledronate—osteoporosis	0.000115	0.000575	CcSEcCtD
Rifaximin—Vomiting—Conjugated Estrogens—osteoporosis	0.000112	0.000562	CcSEcCtD
Rifaximin—Urticaria—Estradiol—osteoporosis	0.000112	0.000562	CcSEcCtD
Rifaximin—Abdominal pain—Estradiol—osteoporosis	0.000111	0.000559	CcSEcCtD
Rifaximin—Body temperature increased—Estradiol—osteoporosis	0.000111	0.000559	CcSEcCtD
Rifaximin—Rash—Conjugated Estrogens—osteoporosis	0.000111	0.000557	CcSEcCtD
Rifaximin—Dermatitis—Conjugated Estrogens—osteoporosis	0.000111	0.000557	CcSEcCtD
Rifaximin—Headache—Conjugated Estrogens—osteoporosis	0.00011	0.000554	CcSEcCtD
Rifaximin—Nausea—Zoledronate—osteoporosis	0.000109	0.000545	CcSEcCtD
Rifaximin—NR1I2—Gene Expression—ESR2—osteoporosis	0.000106	0.00331	CbGpPWpGaD
Rifaximin—Nausea—Conjugated Estrogens—osteoporosis	0.000105	0.000525	CcSEcCtD
Rifaximin—Hypersensitivity—Estradiol—osteoporosis	0.000104	0.000521	CcSEcCtD
Rifaximin—Asthenia—Estradiol—osteoporosis	0.000101	0.000508	CcSEcCtD
Rifaximin—Pruritus—Estradiol—osteoporosis	9.97e-05	0.000501	CcSEcCtD
Rifaximin—Diarrhoea—Estradiol—osteoporosis	9.64e-05	0.000484	CcSEcCtD
Rifaximin—CYP3A4—Biological oxidations—CYP27A1—osteoporosis	9.63e-05	0.00301	CbGpPWpGaD
Rifaximin—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—osteoporosis	9.53e-05	0.00298	CbGpPWpGaD
Rifaximin—CYP3A4—Metapathway biotransformation—CYP27A1—osteoporosis	9.5e-05	0.00297	CbGpPWpGaD
Rifaximin—Dizziness—Estradiol—osteoporosis	9.32e-05	0.000468	CcSEcCtD
Rifaximin—Vomiting—Estradiol—osteoporosis	8.96e-05	0.00045	CcSEcCtD
Rifaximin—Rash—Estradiol—osteoporosis	8.88e-05	0.000446	CcSEcCtD
Rifaximin—Dermatitis—Estradiol—osteoporosis	8.88e-05	0.000446	CcSEcCtD
Rifaximin—Headache—Estradiol—osteoporosis	8.83e-05	0.000443	CcSEcCtD
Rifaximin—NR1I2—Gene Expression—VDR—osteoporosis	8.41e-05	0.00263	CbGpPWpGaD
Rifaximin—Nausea—Estradiol—osteoporosis	8.37e-05	0.00042	CcSEcCtD
Rifaximin—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—osteoporosis	7.06e-05	0.00221	CbGpPWpGaD
Rifaximin—NR1I2—Generic Transcription Pathway—MYC—osteoporosis	6.94e-05	0.00217	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—ESR1—osteoporosis	6.43e-05	0.00201	CbGpPWpGaD
Rifaximin—CYP3A4—Phase 1 - Functionalization of compounds—POMC—osteoporosis	5.72e-05	0.00179	CbGpPWpGaD
Rifaximin—CYP3A4—Biological oxidations—CYP19A1—osteoporosis	5.06e-05	0.00158	CbGpPWpGaD
Rifaximin—CYP3A4—Metapathway biotransformation—CYP19A1—osteoporosis	4.99e-05	0.00156	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—MYC—osteoporosis	3.34e-05	0.00105	CbGpPWpGaD
Rifaximin—CYP3A4—Biological oxidations—POMC—osteoporosis	3.04e-05	0.000951	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—PKM—osteoporosis	2.87e-05	0.000897	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—FDPS—osteoporosis	2.87e-05	0.000897	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—GPD2—osteoporosis	2.72e-05	0.00085	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—PGLS—osteoporosis	2.72e-05	0.00085	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—ATIC—osteoporosis	2.49e-05	0.000778	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—PNP—osteoporosis	2.49e-05	0.000778	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—CA2—osteoporosis	2.11e-05	0.000661	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—OXCT1—osteoporosis	2.11e-05	0.000661	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—MGLL—osteoporosis	2.06e-05	0.000644	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—IDH2—osteoporosis	1.75e-05	0.000548	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—CYP27A1—osteoporosis	1.65e-05	0.000515	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—ACP5—osteoporosis	1.6e-05	0.000501	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—TPI1—osteoporosis	1.49e-05	0.000466	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—P4HB—osteoporosis	1.4e-05	0.000438	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—GAPDH—osteoporosis	1.37e-05	0.00043	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—RAP1A—osteoporosis	1.34e-05	0.000419	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—ENO1—osteoporosis	1.08e-05	0.000339	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—PSMA5—osteoporosis	1.07e-05	0.000334	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—PSMA2—osteoporosis	1.07e-05	0.000334	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—CYP19A1—osteoporosis	8.65e-06	0.000271	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—ADCY5—osteoporosis	7.07e-06	0.000221	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—GPX1—osteoporosis	7.05e-06	0.00022	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—MTHFR—osteoporosis	6.5e-06	0.000203	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—POMC—osteoporosis	5.2e-06	0.000163	CbGpPWpGaD
